Clinical trials: Patients on Chemotherapy
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a…
- Trial name
- NCT07697560
- Testing
- AH-008 for Injection, 150 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
The study compares the overall survival (OS) of FH-006 and the second-line chemotherapy selected by the investigators for treating esophageal squamous cell carcinoma patients.
- Trial name
- NCT07790380
- Testing
- FH-006, Paclitaxel, Docetaxel, Irinotecan
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer
- Trial name
- RECITE (NCT03362177)
- Testing
- Romiplostim
- Where
- 117 sites in United States, Argentina and 18 more
- Volunteers
- 165 people
- Sponsor
- Amgen
Chemotherapy-induced Anemia, Non-Myeloid Malignancy
HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies
A Phase II clinical trial to evaluate the efficacy and safety of different dosing regimens of HEC53856 tablets compared to rHuEPO injection in participants of the CIA trial.
- Trial name
- NCT07891377
- Testing
- HEC53856 tablet, rHuEPO injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
Peripheral neuropathy is a disorder caused by damage to the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain chemotherapy drugs, such as platinum-based compounds, taxanes…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Peripheral Neuropathic Pain
- Trial name
- NCT07072468
- Testing
- VMD-3866 Gel
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- VM Therapeutics LLC
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
- Trial name
- NCT03937154
- Testing
- Romiplostim
- Where
- 34 sites in United States, Argentina and 8 more
- Volunteers
- 145 people
- Sponsor
- Amgen
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as…
- Trial name
- NCT07226986
- Testing
- AMO959, AAA617, Enzalutamide
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Chemotherapy-induced Peripheral Neuropathy
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy.
- Trial name
- NCT07765446
- Testing
- SIR2501
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sironax USA, Inc.
Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV)
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV), Postoperative Nausea and Vomiting
- Trial name
- NCT07868861
- Testing
- NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better.
- Conditions
- Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly
- Trial name
- NCT06959277
- Testing
- Walkasins, Fall Prevention Training
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- RxFunction Inc.
Patients With Chemotherapy-Induced Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
- Trial name
- NCT07286032
- Testing
- Hetrombopag Olamine
- Where
- 51 sites in United States, Bulgaria and 9 more
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections.
- Conditions
- Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
- Trial name
- NCT06848348
- Testing
- Halneuron, Halneuron (Open Label Extension)
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dogwood Therapeutics Inc.
Chemotherapy-Induced Nausea and Vomiting (CINV)
QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration
This is a single-center, single-dose, randomized, open-label, crossover study. Forty-two healthy male and female participants will be enrolled.
- Trial name
- NCT07817004
- Testing
- apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
- Conditions
- Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Trial name
- eVOLVE-02 (NCT06535607)
- Testing
- Volrustomig, Cisplatin, Carboplatin
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Skin Barrier to Water Loss, Skin Health
Apple Peptide Complex for Post-Surgical and Aesthetic Skin Recovery
This clinical study evaluates a topical botanical formulation for supporting skin recovery following invasive and non-invasive aesthetic procedures.
- Conditions
- Skin Barrier to Water Loss, Skin Health, Skin Discoloration, Skin Irritation
- Trial name
- APC-SKIN (NCT07807085)
- Testing
- Apple Peptide Complex Post-Aesthetic Care Protocol
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Grow Out Oils Clinical Aromatherapy Company
Chemotherapy Induced Anemia
A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy
The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.
- Trial name
- NCT06075030
- Testing
- AND017
- Volunteers
- 36 people
- Sponsor
- Kind Pharmaceuticals LLC
Prostate Cancer (Adenocarcinoma), Prostate Biopsy
RegisterPROS - A Registry for Prostate Cancers
Prostate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT).
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Biopsy, Prostatectomy, Radioligand
- Trial name
- RegisterPROS (NCT06872619)
- Testing
- PROSTest
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Chemotherapy Induced Alopecia, Chemotherapy Side Effects
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia
- Trial name
- NCT07397325
- Testing
- DA-020, DA-020 and Hyperforin
- Where
- 2 sites in Brazil, Italy
- Volunteers
- 60 people
- Sponsor
- Applied Biology, Inc.
Chemotherapy-Induced Alopecia
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
The goal of this clinical trial is to learn if Compound 31543 (topical calcitriol) for treatment of hair-loss in patients with a diagnosis of breast cancer, gynecologic cancer or sarcomas receiving a taxane-based chemotherapy is…
- Trial name
- NCT01588522
- Testing
- Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- BPGbio